Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Epigenetix Raises $88M in Series D Funding Round

NEW YORK – Cambridge Epigenetix said on Tuesday that it has raised $88 million in a Series D financing round.

Singapore's Temasek led the round, joined by new investors, including Third Point, and existing investors, including GV, New Science Ventures, Ahren Innovation Capital, and Sequoia.

The Cambridge, UK-based company said it would use the proceeds to commercialize its methylation sequencing technology. The firm's product detects methylated cytosine as well as the four DNA bases. The firm said it expects to begin selling kits and software in early 2022. 

"Our sequencing technology works with all sequencers and enhances their accuracy as opposed to replacing or competing with them," Shankar Balasubramanian, founder of Cambridge Epigenetix, said in a statement. "Further, our technology has the potential to dramatically reduce the cost of genome sequencing, as the low sample requirement and streamlined workflow facilitate its cost-effectiveness and ease of use without sacrificing accuracy." 

The round brings the total amount of fundraising for Cambridge Epigenetix to around $146 million. The firm raised $21 million in 2016.

The firm added that it is working on a "six-letter" kit.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.